Dr. Chengguo Xing’s Kava Clinical Study Makes the Cover of Cancer Prevention Research

Kava’s reputation in preventing cancer just received a boost from the American Association for Cancer Research. The May 2020 cover of the organization’s flagship journal, Cancer Prevention Research, featured a clinical study on kava led by Chengguo “Chris” Xing, Ph.D., a professor of medicinal chemistry and the Frank A. Duckworth Eminent Scholar Chair in the UF College of Pharmacy and a member of the UF Health Cancer Center.

In the pilot clinical trial, Xing and his colleagues evaluated the effects of a seven-day course of kava capsules on tobacco carcinogen metabolism and tobacco usage in active smokers. The results from the study suggest that kava’s twofold cancer prevention mechanism reduces the toxicity of a certain carcinogenic metabolite and relaxes the user, which reduces tobacco cravings.

Learn more about Dr. Chengguo Xing’s Kava Clinical Study Makes the Cover of Cancer Prevention Research.